Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Insights
  5. Venture Financing

Venture financing

Evaluate

July 07, 2023

Venture financing ticks up for biopharma

But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.

April 04, 2023

A lean first quarter for venture-backed developers

While venture investors keep the purse strings tight, they themselves continue to enjoy fundraising success.

Article image
Vantage logo
January 24, 2023

Medtech investments hold up despite market turmoil

Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.

Article image
Vantage logo
January 12, 2023

Biopharma’s venture year ends with another dip

Last year saw plenty of cash deployed, but with sums shrinking each quarter the stage is set for further retrenchment.

Article image
Vantage logo
October 14, 2022

Medtech bleeds corporate venture cash

Overall venture investment in the sector remains steady, but the big strategics back off.

Article image
Vantage logo
October 06, 2022

Venture investors keep the purse strings tight

Third-quarter numbers show that biopharma venture investments are firmly back in 2018 territory.

Article image
Vantage logo
August 12, 2022

Trad device start-ups catch the cash

Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.

Article image
Vantage logo
August 02, 2022

Corporate venture investors stay strong

The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.

Article image
Vantage logo
July 22, 2022

Venture financing holds steady for device makers

Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.

Article image
Vantage logo
July 08, 2022

The retrenchment begins for venture funding

The gloomy climate for biotech is now taking its toll on private companies too.

Article image
Vantage logo
April 05, 2022

Venture funding stays strong despite the gloom

But how long can the money keep rolling in?

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...
Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up